ClinicalTrials.gg
RecruitingNCT04206215Updated Aug 18, 2026

Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome

An interventional study of transcranial Direct Current Stimulation (tDCS) and Transcranial Ultrasound (TUS) in Chronic Pain and Carpal Tunnel Syndrome, sponsored by Spaulding Rehabilitation Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Spaulding Rehabilitation Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2021; still recruiting 5 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
95
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Chronic Pain by Spaulding Rehabilitation Hospital — 3 open to participants now, 5 under way, none of them phase 3. Chronic Pain · Spaulding Rehabilitation Hospital.

Planned enrollment
2nd of 15
95 · median 38
Started
2021
with 1 other
No phase
15 of 16
3 open now
Registered
13th of 16
by date

Among the 16 studies in Chronic Pain by Spaulding Rehabilitation Hospital, this one is the 2nd largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2021, is one of 15 with no phase, and was the 13th registered.

Chronic Pain

3,228 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

3 of the 16 studies in Chronic Pain by Spaulding Rehabilitation Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Chronic Pain by Spaulding Rehabilitation Hospital, or all of them as a file.
02

Study summary

The purpose of this study is to assess the effects of tDCS in combination with TUS for the treatment of pain in subjects with Carpal Tunnel Syndrome. The investigators hypothesize that there will be a decrease in pain levels with active stimulation, when compared to sham stimulation.

03

Conditions studied

  • Chronic Pain
  • Carpal Tunnel Syndrome

Keywords

  • transcranial Direct Current Stimulation
  • Transcranial Ultrasound
  • Noninvasive brain stimulation
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to provide to participate in the study
  2. Subjects between 18 to 80 years old
  3. Having symptomatic CTS spreading within or beyond the median nerve distribution (demonstrating 'extra-median spread'), involving at least 1 wrist, with chronic pain as defined by International Association for the Study of Pain (existing pain for at least 6 months and having pain on at least half the days in the past 6 months with an average of at least a 3 on a 0-10 VAS scale).
  4. Pain resistant to therapies of chronic pain (pain still present at lower levels most of the time following therapy)
  5. Must have the ability to feel pain as self-reported.

Exclusion criteria

Exclusion Criteria:

  1. Subject is pregnant
  2. to tDCS+TUS:

    1. intracranial metal implant
    2. implanted brain medical devices
  3. History of alcohol or drug abuse within the past 6 months as self-reported
  4. Use of carbamazepine within the past 6 months as self-reported
  5. Suffering from major depression (with a PHQ-9 score of ≥20)
  6. History of neurological disorders involving stroke, brain tumors, or epilepsy with residual neurological symptoms as self-reported (note patients will also be evaluated via EEG at baseline about 1 week prior to stimulation and any patient showing abnormal EEG activity will be removed))
  7. History of unexplained fainting spells as self-reported
  8. History of head injury resulting in more than a momentary loss of consciousness as self-reported and with current neurological deficits
  9. History of intracranial neurosurgery as self-reported
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
95 participants (estimated)

Study arms

  • Experimental
    Active tDCS + Active TUS

    Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS).

    Device: transcranial Direct Current Stimulation (tDCS) · Device: Transcranial Ultrasound (TUS)

  • Sham comparator
    Sham tDCS + Sham TUS

    Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).

    Device: transcranial Direct Current Stimulation (tDCS) · Device: Transcranial Ultrasound (TUS)

Interventions

  • Devicetranscranial Direct Current Stimulation (tDCS)

    Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. In the sham group, the tDCS device will not be active for the full 20 minutes.

  • DeviceTranscranial Ultrasound (TUS)

    Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.

06

What researchers measure

Primary outcomes

  1. Visual Analogue Score (VAS)

    Changes in the Visual Analogue Scale (VAS) for pain will be measured in order to determine whether anodal transcranial direct current stimulation in conjunction with transcranial ultrasound is effective in reducing pain in subjects with Carpal Tunnel Syndrome. The VAS scale goes from 0 up to 10, where 0 means no pain at all and 10 means the worst imaginable pain.

    Time frame: 9 weeks

Secondary outcomes

  1. Verbal Rating Scale (VRS)

    Changes in the Verbal Rating Scale (VRS) for pain will be measured in order to determine whether anodal transcranial direct current stimulation in conjunction with transcranial ultrasound is effective in reducing pain in subjects with Carpal Tunnel Syndrome. The VRS minimum value is no pain and the maximum value is severe pain. Being severe pain the worst outcome.

    Time frame: Measured for approximately for a total 9 weeks

  2. Visual Analog Mood Scale (VAMS)

    The investigators will measure safety of tDCS and TUS by measuring changes in the Visual Analog Mood Scale. This scale will range from zero (low or worst mood) to 10 on anxiety, depression, sleepiness and stress.

    Time frame: Measured for approximately for a total 9 weeks

  3. Montreal Cognitive Assessment (MOCA)

    The investigators will monitor the safety of tDCS and TUS in subjects by measuring any changes in cognition, attention, and focus with the MOCA. MOCA scores range between 0 and 30, a score of 26 and higher generally considered normal.

    Time frame: Measured for approximately for a total 9 weeks

  4. tDCS Side Effects Questionnaire

    At each session, subjects will complete a questionnaire to evaluate potential adverse effects of stimulation (headache, neck pain, mood alterations, and seizures) on a 4-point scale, where 1 is absent and 4 is severe. The scale will also be administered at the follow-ups.

    Time frame: Measured for approximately for a total 9 weeks

  5. Patient Health Questionnaire (PHQ-9)

    The investigators will measure safety of tDCS and TUS by measuring changes of mood through the PHQ-9. The scoring goes from 0 to 27, where 0 is no depression and 27 is severe depression.

    Time frame: Measured for approximately for a total 9 weeks

  6. Multidimensional Pain Inventory (MPI)

    The investigators will monitor the impact of pain with the MPI of tDCS and TUS. It consist in 3 sections (Pain Impact , responses by significant others, activities and each item is rated on a 7-point scale (0-6), where higher scores represent severe symptoms .

    Time frame: Measured for approximately for a total 9 weeks

  7. Neuropathic Pain Symptom Inventory (NPSI)

    The investigators will monitor the changes of neuropathic pain in subjects going through the study before and after tDCS and TUS. It include 12 items in total, this tool evaluates mean pain intensity in the last 24 hours in a numeric scale from zero (no pain) to 10 (worst imaginable pain). Total pain intensity score may be calculated by the sum of 10 descriptors

    Time frame: Measured for approximately for a total 9 weeks

  8. Temporal Summation (TS)

    The investigators will monitor the changes of temporal summation in the study before and after tDCS and TUS. This will be assessed by Von Frey filaments. This is assessed by having the participant rate their pain after a single stimulus (6.65, 300 g) applied for 0.5 s and then again after a series of 10 (6.65, 300 g) stimuli are applied at 1-s intervals.

    Time frame: Measured for approximately for a total 9 weeks

  9. Conditioned pain modulation (CPM)

    Changes in the conditioned pain modulation will be measured in order to determine whether anodal transcranial direct current stimulation in conjunction with transcranial ultrasound is effective in changing the conditioned pain modulation system in subjects with Carpal Tunnel Syndrome. This will be assessed by applying pressure with an algometer.

    Time frame: Measured for approximately for a total 9 weeks

  10. Vibration Detection Threshold (VDT)

    Changes in the vibration detection threshold will be measured , this is performed with a Rydel-Seiffer tuning fork (64 Hz, 8/8 scale) placed on the skin surface and is determined by asking the participant to tell the examiner when the vibration is no longer felt.

    Time frame: Measured for approximately for a total 9 weeks

  11. Michigan Hand Outcomes Questionnaire (MHQ)

    This a hand-specific outcomes instrument that measures outcomes of patients with conditions of, or injury to, the hand or wrist. The MHQ contains six distinct scales: overall hand function, activities of daily living , pain, work performance, aesthetics, and patient satisfaction with hand function. They are scored from 0 - 100 in which 100 is the best possible ability

    Time frame: Measured for approximately for a total 9 weeks

  12. Boston Carpal Tunnel Questionnaire

    This is an instrument specifically designed for Carpal Tunnel Syndrome (CTS) and validated for CTS therapy assessments (consisting of the Functional Status Scale and Symptom Severity Scale scores. The symptom severity scale has 11 questions scored from 1 point (mildest) to 5 points (most severe).

    Time frame: Measured for approximately for a total 9 weeks

  13. The Medical Outcomes Study 36-Item Short Form (SF-36)

    This a generic health status instrument that measures 8-health related concepts using 36 questions and provides a profile of functional health and well-being scores. It also provides a psychometrical index of physical and mental health. Each scale is transformed into a 0-100 scale. The lower the score the more disability. The higher the score the less disability

    Time frame: Measured for approximately for a total 9 weeks

  14. Electroencephalography (EEG)

    Investigators will measure electroencephalogram activity to monitor safety. Baseline recordings will be reviewed to ensure that there are no potential electroencephalographic safety criteria prior to stimulation. This qualitative analysis will focus on pathological EEG activity such as epileptiform discharges or persistent focal slowing.

    Time frame: Measured for approximately for a total 3 weeks

  15. Strength (grip and pinch)

    Strength will be assessed using a grip dynamometer and a pinch dynamometer

    Time frame: Measured for approximately for a total 9 weeks

  16. Range of Motion (ROM)

    The investigators will assess active and passive ROM in the elbow, forearm, wrist, thumb, digits

    Time frame: Measured for approximately for a total 9 weeks

  17. Thumb Reaching Test

    Subject will be asked to reach the base of the little finger with their thumb. The task will be repeated up to 10 times. Primary data will be taken from inertial sensors placed on the thumb and little finger.

    Time frame: Measured for approximately for a total 9 weeks

  18. Reach to Pinch

    Subject will be asked to perform a reach to pinch task . The task will be repeated up to 10 times. Primary data will be taken from camera and accelerometers/gyroscopes placed on the thumb and index finger.

    Time frame: Measured for approximately for a total 9 weeks

  19. Wrist Flexion-Extension:

    Subject will be asked to flex-extend their wrist up to 10 times. Primary data will be taken from an accelerometer/gyroscope placed on the wrist and the camera.

    Time frame: Measured for approximately for a total 9 weeks

07

Study locations

1 of 1 sites recruiting
  • Spaulding Rehabilitation Network Research Institute
    Charlestown, Massachusetts 02129, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2021 (actual). Primary completion is estimated for Jul 2027, 74 months after the start.

Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 74 months is above that.

Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2019
First posted
Dec 20, 2019
StartActual
Apr 16, 2021
Primary completionEst.
Jul 2, 2027
CompletionEst.
Dec 28, 2027
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04206215
Collaborators
Highland Instruments, Inc.
Responsible party
Felipe Fregni, MD, PhD, MPH (Principal Investigator, Spaulding Rehabilitation Hospital) — Principal investigator
First posted
Dec 20, 2019
Start date
Apr 16, 2021
Primary completion
Jul 2, 2027 (estimated)
Completion
Dec 28, 2027 (estimated)
Last update
Aug 18, 2026

Study contacts

Felipe Fregni, MD PhD mph
Contact
ffregni@partners.org
617-952-6156
Meghan Whalen, BS
Contact
mwhalen7@partners.org
617-952-6158
Felipe Fregni, MD PhD MPH
principal investigator · Spaulding Rehabilitation Network

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion